ArticleEuropean journal of clinical pharmacology2026
Population pharmacokinetics of methylprednisolone in neonates and paediatric patients undergoing cardiac surgery with cardiopulmonary bypass.
Article in European journal of clinical pharmacology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeMethylprednisolone is used during paediatric cardiac surgery with cardiopulmonary bypass to attenuate the systemic inflammatory response. However, developmental differences in drug disposition and cardiopulmonary bypass-related factors contribute to pharmacokinetic variability in this population. We aimed to develop a population pharmacokinetic model of methylprednisolone in neonates and paediatric patients undergoing cardiac surgery with cardiopulmonary bypass and to identify factors associated with its pharmacokinetic variability.
methodsData were pooled from four prospective clinical studies including 93 patients aged 1 to 574 days undergoing cardiac surgery with cardiopulmonary bypass. Methylprednisolone was administered as an intravenous bolus after anaesthesia induction or into the cardiopulmonary bypass circuit at 5 or 30 mg/kg. Plasma concentrations were measured perioperatively. A nonlinear mixed-effects model was developed using NONMEM. Covariate effects were evaluated. Model evaluation included goodness-of-fit plots, normalized prediction distribution errors, sampling importance resampling, and prediction-corrected visual predictive checks.
resultsA one-compartment model with first-order elimination adequately described the data. The final model identified body weight, an empirical postmenstrual-age effect on clearance, and operation-group differences in the apparent volume of distribution as significant determinants of methylprednisolone pharmacokinetics. Interindividual variability was estimated for clearance (48.1%) and volume of distribution (19.9%). Model evaluation supported the predictive performance of the final model.
conclusionWe developed a population pharmacokinetic model for methylprednisolone in paediatric patients undergoing cardiac surgery with cardiopulmonary bypass. The model identifies body weight, postmenstrual age and operation group as determinants of pharmacokinetic variability. It provides a descriptive framework for characterizing methylprednisolone disposition in this heterogeneous population. TRIAL REGISTRATION NUMBER AND DATE: EudraCT 2008-007413-76 2008-12-23.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.